# Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

> **NCT05716009** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 36 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dose Escalation -tagraxofusp-erzs
- **DRUG:** Dose Expansion at RP2D -tagraxofusp-erzs

## Key facts

- **NCT ID:** NCT05716009
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2027-12-25
- **Final completion:** 2028-12-25
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05716009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05716009, "Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05716009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*